Literature DB >> 12946561

Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study.

Brigitte Leininger-Muller1, Aline Hoy, Bernard Herbeth, Michèle Pfister, Jean Marie Serot, Marina Stavljenic-Rukavina, Luis Massana, P Passmore, Gérard Siest, Sophie Visvikis.   

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Epidemiological and molecular genetic studies have shown the existence of several genes associated with increased risk of AD, the major genetic susceptibility locus coding for apolipoprotein E (apoE). A polymorphism in the myeloperoxidase gene (MPO) has previously been associated with AD susceptibility. However, results in the literature are controversial and seem to be dependent on several factors such as gender, apoE polymorphism or the genetic structure of the population. We investigated MPO G-463A and apoE polymorphism in 265 cases and 246 controls from the ApoEurope Study. In females, we found a significant association between MPO genotype and AD (P=0.034), GG genotype frequency being lower in cases (52.4%) as compared to controls (64.2%). In men, there was no significant effect of MPO polymorphism. No interaction was found between MPO polymorphism and apoE epsilon 4 allele. In conclusion, the G-463A polymorphism of MPO was statistically associated with AD in a gender-specific manner. However, given the low significance of P value we suggest no causal effect of the MPO gene in AD, as also evidenced in a recent meta-analysis. Our results support the hypothesis of a possible linkage disequilibrium between the MPO G-463A gene polymorphism and another functional variant involved in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946561     DOI: 10.1016/s0304-3940(03)00795-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Biosynthesis of human myeloperoxidase.

Authors:  William M Nauseef
Journal:  Arch Biochem Biophys       Date:  2018-02-03       Impact factor: 4.013

2.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

3.  Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.

Authors:  Richard A Maki; Vladimir A Tyurin; Robert C Lyon; Ronald L Hamilton; Steven T DeKosky; Valerian E Kagan; Wanda F Reynolds
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

4.  Myeloperoxidase gene sequence variations are associated with low-density-lipoprotein characteristics.

Authors:  Guillaume Dolley; Benoit Lamarche; Jean-Pierre Després; Claude Bouchard; Louis Pérusse; Marie-Claude Vohl
Journal:  J Hum Genet       Date:  2008-03-06       Impact factor: 3.172

5.  Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease.

Authors:  Wanda F Reynolds; Isabelle Sermet-Gaudelus; Valérie Gausson; Marie-Noëlle Feuillet; Jean-Paul Bonnefont; Gérard Lenoir; Béatrice Descamps-Latscha; Véronique Witko-Sarsat
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

6.  The association of MPO gene promoter polymorphisms with Alzheimer's disease risk in Chinese Han population.

Authors:  Wenzhen Ji; Yu Zhang
Journal:  Oncotarget       Date:  2017-11-06

7.  Myeloperoxidase Deficiency Inhibits Cognitive Decline in the 5XFAD Mouse Model of Alzheimer's Disease.

Authors:  Rotem Volkman; Tali Ben-Zur; Anat Kahana; Ben Zion Garty; Daniel Offen
Journal:  Front Neurosci       Date:  2019-09-24       Impact factor: 4.677

Review 8.  Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review.

Authors:  Francesca Zimetti; Maria Pia Adorni; Judit Marsillach; Cinzia Marchi; Alessandro Trentini; Giuseppe Valacchi; Carlo Cervellati
Journal:  Oxid Med Cell Longev       Date:  2021-01-08       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.